Influence of ITPA Polymorphisms on Decreases of Hemoglobin During Treatment with Pegylated Interferon, Ribavirin, and Telaprevir
Influence of ITPA Polymorphisms on Decreases of Hemoglobin During Treatment with Pegylated Interferon, Ribavirin, and Telaprevir
复制标题
DOI：
10.1002/hep.24058
复制
发表时间：
2011-02-01
期刊：
影响因子：
13.5
通讯作者：
Kumada, Hiromitsu
中科院分区：
文献类型：
--
作者：
Suzuki, Fumitaka;Suzuki, Yoshiyuki;Kumada, Hiromitsu
在聚乙二醇干扰素（PEG-IFN）和利巴韦林（RBV）治疗期间，肌苷三磷酸酶（ITPA）基因多态性影响贫血，但其在PEG-IFN、RBV和特拉匹韦三联治疗期间的作用尚不清楚。三联治疗12周，然后PEG-IFN和RBV 12周，给予49例RBV敏感（CC在rs 1127354）和12例RBV耐药（CA/AA）ITPA基因型谁已感染丙型肝炎病毒（H CV）基因型1。在第2周时，CC基因型患者的血红蛋白水平下降幅度大于CA/AA基因型患者（-1.63 +/- 0.92 vs. -0.48 +/- 0.75 g/dL，P = 0.001）和第4周（-3.5 +/- 1.1 vs. -2.2 +/- 0.96，P = 0.001），以及治疗结束时（-2.9 +/- 1.1 vs. -2.0 +/- 0.86，P = 0.013）。血红蛋白的危险因素50岁，体重指数（BMI）
Polymorphisms of the inosine triphosphatase (ITPA) gene influence anemia during pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with PEG-IFN, RBV, and telaprevir are not known. Triple therapy for 12 weeks, followed by PEG-IFN and RBV for 12 weeks, was given to 49 patients with RBV-sensitive (CC at rs1127354) and 12 with RBV-resistant (CA/AA) ITPA genotypes who had been infected with hepatitis C virus (H CV) of genotype 1. Decreases in hemoglobin levels were greater in patients with CC than CA/AA genotypes at week 2 (-1.63 +/- 0.92 vs. -0.48 +/- 0.75 g/dL, P = 0.001) and week 4 (-3.5 +/- 1.1 vs. -2.2 +/- 0.96, P = 0.001), as well as at the end of treatment (-2.9 +/- 1.1 vs. -2.0 +/- 0.86, P = 0.013). Risk factors for hemoglobin 50 years, body mass index (BMI)